Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

282.92 -1.32 (-0.46%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)
From Insulet Corporation
Via Business Wire
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Wall Street Mixed Ahead Of Fed Meeting, Alphabet Sinks: What's Driving Markets Wednesday? ↗
U.S. stocks traded mixed at midday Wednesday, as investors remained cautious ahead of the Federal Reserve’s upcoming policy decision, with Chair Jerome Powell set to speak at 2:30 p.m. ET. 
Via Benzinga
Topics Economy
News headline image
What To Expect From Insulet’s (PODD) Q1 Earnings
Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be announcing earnings results tomorrow after the bell. Here’s what to expect. 
Via StockStory
News headline image
1 Growth Stock with Impressive Fundamentals and 2 to Think Twice About
Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID... 
Via StockStory
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Discover which S&P500 stocks are making waves on Tuesday. ↗
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session. 
Via Chartmill
News headline image
Exploring the top movers within the S&P500 index during today's session. ↗
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
Which S&P500 stocks are gapping on Tuesday? ↗
Looking for the S&P500 stocks that are experiencing notable gaps on Tuesday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session. 
Via Chartmill
News headline image
The Analyst Verdict: Insulet In The Eyes Of 7 Experts ↗
 
Via Benzinga
News headline image
This Saia Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
1 Healthcare Stock Worth Your Attention and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and... 
Via StockStory
Topics Stocks
News headline image
Insulet Appoints Ashley McEvoy President and CEO
From Insulet Corporation
Via Business Wire
News headline image
INSULET CORP (NASDAQ:PODD) qualifies as a high growth stock and is consolidating. ↗
Based on fundamental and technical analysis of NASDAQ:PODD we conclude: INSULET CORP (NASDAQ:PODD): a strong growth stock preparing for the next leg up?. 
Via Chartmill
News headline image
Thursday's pre-market session: top gainers and losers in the S&P500 index ↗
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements. 
Via Chartmill
News headline image
$100 Invested In Insulet 15 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
What's Driving the Market Sentiment Around Insulet? ↗
 
Via Benzinga
News headline image
BD, Teleflex, Insulet, UFP Technologies, and Haemonetics Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%,... 
Via StockStory
Topics Economy Government World Trade
News headline image
Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)
Let’s dig into the relative performance of Masimo (NASDAQ:MASI) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. 
Via StockStory
Topics Artificial Intelligence
News headline image
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry ↗
Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest strain. Large biopharma firms remain protected, while medtech companies... 
Via Benzinga
Topics Government World Trade
News headline image
Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock? ↗
Based on a technical and fundamental analysis of NASDAQ:PODD we conclude: INSULET CORP (NASDAQ:PODD)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
News headline image
Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025
From Insulet Corporation
Via Business Wire
News headline image
Q4 Earnings Highlights: iRhythm (NASDAQ:IRTC) Vs The Rest Of The Patient Monitoring Stocks
Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons Investors Love Insulet (PODD)
Over the past six months, Insulet has been a great trade. While the S&P 500 was flat, the stock price has climbed by 14.6% to $265.87 per share. This was partly due to its solid quarterly results, and... 
Via StockStory
Topics Stocks
News headline image
Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers
Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. 
Via StockStory
Topics Artificial Intelligence
News headline image
Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections
From Insulet Corporation
Via Business Wire
News headline image
Insulet Announces Pricing of Senior Notes Due 2033
From Insulet Corporation
Via Business Wire
News headline image
Insulet Announces Proposed Financing Transactions
From Insulet Corporation
Via Business Wire
News headline image
Insulet Expands Omnipod® 5 to Four More International Markets
From Insulet Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.